Advice

Following an abbreviated submission

Aripiprazole tablets 5mg (Abilify) are accepted for restricted use in NHS Scotland for the treatment of schizophrenia. Where aripiprazole is an appropriate antipsychotic, this new dosage is restricted to patients who may benefit from a dose reduction to 5mg daily, taking account of SMC advice issued in August 2004. This 5mg tablet is the same price as the 10mg and 15mg tablets

Download detailed advice28KB (PDF)

Download

Medicine details

Medicine name:
Aripiprazole (Abilify®)
SMC ID:
187/05
Indication:
Schizophrenia
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Central nervous system
Submission type
Abbreviated
Status
Restricted
Date advice published
11 July 2005